Clinical Trial

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

Study acronym: CARTD-BG-1
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 26, 2023 (before its estimated April 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other treatments). This is a first in human study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-18.
Trial Details
NCT Number NCT06097455
Lead Sponsor Fundacion Clinic per a la Recerca Biomédica
Conditions Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Enrollment 40 participants
Start Date 2024-01-15
Primary Completion 2025-04-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2023-10-26